Division of Hematology and Oncology

June 16, 2022

Breast cancer biomarkers of response

Vanderbilt researchers have identified blood-based biomarkers associated with complete responses to neoadjuvant chemotherapy in patients with breast cancer.

April 25, 2022

Molecular testing across tumor types

The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.

April 21, 2022

Biltibo receives career development award to support hematology research

Vanderbilt’s Eden Biltibo, MD, a clinical fellow in the Division of Hematology and Oncology, has been selected for the 2022 ASH-CIBMTR-ASTCT Career Development Award.

March 24, 2022

Berlin named interim leader of Hematology and Oncology

Jordan Berlin, MD, has been appointed interim leader of Vanderbilt’s Division of Hematology and Oncology in the Department of Medicine.

February 17, 2022

Park named director of Vanderbilt-Ingram Cancer Center

Ben Ho Park, MD, PhD, deputy director of the Vanderbilt-Ingram Cancer Center, has been named the center’s new director.

February 17, 2022

Grant to support Haake’s research on kidney cancer

Kure It Cancer Research has awarded a $200,000 grant to support kidney cancer research by Vanderbilt’s Scott Haake, MD.